Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enfuvirtide: the first HIV fusion inhibitor

1 Mar 2005

Abstract excerpt

Highly active antiretroviral therapy, a combination of antiretrovirals to treat HIV-infected individuals, may fail for a number of reasons, including the selection of genetic mutations which confer resistance to the antiretroviral drugs, and poor adherence or treatment discontinuation resulting from drug toxicity. Treatment-experienced patients, who have failed therapy owing to the emergence of drug-resistant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV/AIDS Research and Interventions
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15794736
DOI: 10.1517/14656566.6.3.453

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enfuvirtide: the first HIV fusion inhibitorPMID 15794736Read ↗

Resistance to enfuvirtide, the first HIV fusion inhibitor.Semantic proximity Read ↗

HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications.Semantic proximity Read ↗

Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function.Semantic proximity Read ↗

HIV fusion and its inhibition in antiretroviral therapySemantic proximity Read ↗

Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.Semantic proximity Read ↗

CCR5 inhibitors: up and coming new agents.Semantic proximity Read ↗

The development of a new fusion inhibitor for the treatment of HIVSemantic proximity Read ↗

Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and InhibitionSemantic proximity Read ↗

Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strainsSemantic proximity Read ↗

Peptide-Based Inhibitors of the HIV Envelope Protein and Other Class I Viral Fusion ProteinsSemantic proximity Read ↗

Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor.Semantic proximity Read ↗

HIV-1 Entry and Membrane Fusion InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.